Latest news with #NationalBrainTumorSociety
Yahoo
08-07-2025
- Health
- Yahoo
Hope on the Horizon: Cutting-Edge Therapies Redefine Outcomes in Glioblastoma Multiforme Treatment making the global market to nearly double by 2033 and grow with a CAGR of 8.5%
The glioblastoma multiforme treatment market is expected to grow significantly and reach USD 6.1 billion by 2033, driven by a rising prevalence, growing R&D investment in novel therapies and favorable reimbursement support. New vaccine-based approaches are emerging as key areas of focus. Chicago, July 08, 2025 (GLOBE NEWSWIRE) -- The global glioblastoma multiforme treatment market was valeud at US$ 3.0 billion in 2024 and is expected to reach USD 6.1 billion by 2033, growing at a CAGR of 8.5% from 2025-2033. This expansion is fueled by rising disease prevalence, advances in diagnostics, growing R&D investments, and emerging targeted therapies. However, challenges such as the blood-brain barrier, therapeutic resistance, and limited long-term efficacy constrain progress and deter commercial investment. Despite these hurdles, innovation across therapeutic modalities and supportive technologies is gradually reshaping the treatment landscape. Explore Key Data Points and Forecast Tables in the Free Sample Copy: Glioblastoma Multiforme is the most common type of cancerous brain tumor. It poses significant treatment challenges due to its rapid proliferation, invasive growth, and resistance to conventional therapies. It is characterized by necrosis, microvascular proliferation, and marked cellular atypia. As per the American Association of Neurological Surgeons in 2024, glioblastoma multiforme accounted for 47.7% of malignant brain and CNS tumors, with an incidence of 3.2 per 100,000 and a prevalence of 9.2 per 100,000 in the U.S. According to the National Brain Tumor Society, the median survival is 14.6 months, with only 17% of patients alive after two years and a five-year survival rate of just 6.8%. It is more common in males, peaks between ages 75 – 84, and shows racial disparities, with highest incidence among non-Hispanic white populations. Treatment typically involves surgical resection followed by chemoradiation with temozolomide, which remains the standard of care (SoC). However, recurrence occurs in over 90% of patients within two years. For recurrent cases, bevacizumab (Avastin) and combinations like lomustine-bevacizumab offer modest benefits. Device-based therapies, such as Tumor Treating Fields (TTFields), continue gaining traction with FDA-approved systems like Optune Gio. Novel therapies, including selinexor (NCT04216329) and immune checkpoint inhibitors like nivolumab (NCT04606316), are currently in clinical trials, signaling progress towards durable Forecast (2033) USD 6.1 billion CAGR 8.5% Top Driver (s) Growing Prevalence of glioblastoma multiformeFavorable reimbursement policies Demand for effective treatment Top Trend Adoption of TTFields devices Top Restraint Consistently low survival rates in glioblastoma multiforme Opportunity Unlocked: Glioblastoma Vaccines as the Next Frontier in Immunotherapy Glioblastoma multiforme is hard to treat with conventional therapies. However, breakthroughs in vaccine-based immunotherapy are beginning to reshape the therapeutic landscape, offering new hope for the patients. Research efforts are accelerating around multiple vaccine platforms, including peptide-based, dendritic cell (DC), and mRNA vaccines, highlighting a new era of personalized and immune-driven treatment strategies. Peptide vaccines, such as SurVaxM developed by MimiVax and currently in Phase II clinical trials, are designed to target tumor-specific neoantigens, activating the immune system to selectively attack malignant cells. These personalized vaccines have shown potential in extending progression-free survival and enhancing immune engagement. Similarly, DC vaccines are gaining traction, despite logistical challenges in integration with standard therapies. Notable candidates such as DCVax-L, in Phase III trials for newly diagnosed and recurrent glioblastoma multiforme, and DOC1021, currently in Phase II trials by Diakonos, have demonstrated improved two-year survival rates when administered sequentially after temozolomide (TMZ) chemotherapy, rather than concurrently. Meanwhile, mRNA-based vaccines are emerging as a powerful immunotherapeutic modality, leveraging their rapid development cycle and capacity to induce strong, targeted immune responses against glioblastoma multiforme cells. Their adaptability and precision position them as a key component in next-generation oncology protocols. While the momentum is promising, ongoing research aims to refine delivery systems, address tumor-induced immunosuppression, and explore synergistic combinations with checkpoint inhibitors and standard-of-care therapies. Collectively, the expanding pipeline of glioblastoma vaccines signifies a paradigm shift toward more personalized, immune-based interventions, marking a transformative step forward in the quest for more durable and effective glioblastoma multiforme treatment. Regional Dynamics Shaping the Glioblastoma Multiforme Treatment Landscape The global glioblastoma multiforme treatment market is evolving rapidly, with regional dynamics playing a pivotal role in shaping its growth. North America leads the market, driven by advanced healthcare infrastructure, streamlined regulatory frameworks, and strong R&D investment. The U.S. Consolidated Appropriations Act of 2024 allocated $10 million to establish the Glioblastoma Research Program (GBMRP) under CDMRP, while Canada's Lundin Cancer Fund committed $4 million in 2025 to launch a national glioblastoma multiforme initiative, reinforcing the region's leadership in clinical innovation. Europe follows closely, propelled by coordinated national research strategies and strong public funding. Germany's UNITE Glioblastoma project, supported by the German Research Foundation's Collaborative Research Centers, exemplifies the region's growing commitment to tackling glioblastoma multiforme through advanced research and cross-border collaboration. The Asia-Pacific region is witnessing rapid progress, with governments, academia, and private stakeholders stepping up investment. Japan's conditional approval of DELYTACT (G47∆) the world's first oncolytic virus therapy for malignant gliomas, highlights the region's increasing role in therapeutic innovation. Meanwhile, the Middle East and Africa are in the early stages of glioblastoma multiforme research development. Though challenged by limited infrastructure and funding, emerging efforts from academic centers and private healthcare providers are laying the groundwork for future growth and capacity-building. As glioblastoma multiforme remains one of the most aggressive brain cancers, regional efforts will continue to shape the global response, advancing innovation, access, and treatment outcomes. Recent Advancements and Key Players in the Glioblastoma Therapeutics Market Several prominent players, including Novocure, Roche, Merck & Co., Novartis, Daiichi Sankyo, Allergan, Laminar Pharmaceuticals, Vigeo Therapeutics, Eli Lilly, Incyte Corporation, Kazia Therapeutics, and TVAX Biomedical, are advancing innovation in the glioblastoma treatment landscape. These companies are focused on developing novel therapeutics, targeted drug delivery systems, and strategic collaborations to tackle one of the most aggressive forms of brain cancer. In March 2025, Laminar Pharmaceuticals announced promising results from its ongoing Phase 2b/3 clinical trial (NCT04250922) of LAM561 in newly diagnosed glioblastoma (ndGBM). The randomized, double-blind, placebo-controlled study evaluates LAM561 in combination with standard chemoradiotherapy (radiotherapy and temozolomide). Early data revealed a positive trend in progression-free survival (PFS), particularly in patients with MGMT-methylated tumors. The trial is partially supported by the EU H2020 ClinGlio initiative, reinforcing the importance of public-private partnerships in advancing brain cancer research. Similarly, on June 2, 2025, Sapience Therapeutics presented updated clinical and biomarker data from its ongoing Phase 2 trial of Lucicebtide (formerly ST101) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Lucicebtide, a first-in-class C/EBPβ antagonist, demonstrated encouraging results in glioblastoma patients, further validating its mechanism of action and potential as a novel targeted therapy. Further driving progress, on April 1, 2025, Spanios and GlioGuard announced a strategic partnership to accelerate glioblastoma drug discovery and development. This collaboration aims to deliver more effective and personalized treatment options for glioblastoma multiforme, addressing the urgent need for breakthroughs in one of the most treatment-resistant forms of cancer. These advancements highlight the growing momentum in glioblastoma therapeutics. With continued innovation, clinical progress, and collaborative efforts, the industry is poised to improve patient outcomes and reshape the future of brain cancer treatment. Book a 1:1 Presentation to Discuss Key Trends and Strategic Takeaways: Future Outlook: Evolving the Glioblastoma Multiforme Treatment Landscape The glioblastoma multiforme treatment market is under transformation. By 2030, a combination of drug innovation, device advancement, and integrated care models is expected to redefine survival outcomes for this aggressive brain cancer. Oral therapies currently lead the market, driven by ease of use and improved patient adherence. Injectables follow, offering systemic options like chemotherapies and targeted biologics. Implants, such as localized wafers, remain a niche but vital component post-surgery. Therapies, especially multi-modal regimens, dominate the market and are expanding rapidly, as combination approaches become the clinical standard. The next wave will be led by immunotherapies and immune checkpoint inhibitors, poised to break the disease immune resistance. These emerging treatments will increasingly complement traditional modalities, aiming for longer progression-free and overall survival. Wearable devices, particularly Novocure's Optune Gio, represent a paradigm shift. Future versions will be lighter, more personalized, and AI-integrated, enabling real-time therapy adjustments and remote monitoring, bringing glioblastoma multiforme care closer to the patient. Key Competitors Novocure Roche Merck & Co. Novartis Daiichi Sankyo Allegran Laminar pharmaceuticals Vigeo therapeutics Eli lily Incyte corporation Kazia Therapuetics TVAX Biomedicals Segmentation: Glioblastoma Multiforme Treatment Market By Treatment Type Surgery (Gliadel wafer) Therapies Chemotherapy Temzolomide Lomustine Radiation Therapy Targeted Therapy (Bevacizumab) Others (Delytact) Tumor Treating Fields (TTF) (Optune Gio) By Dosage Form Oral Injectables Implant and TFF Field Device By End Users Hospitals & Clinics (specialty clinics) Cancer Treatment Centers Academic and Research Organizations By Region North America South America Europe Asia Pacific Middle East and Africa Still Have Questions? Contact Us for Clarification or a Custom Data Request: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Health Line
26-06-2025
- Health
- Health Line
Oligodendroglioma
Oligodendroglioma is a rare tumor that develops in the brain with no known cause. It tends to have a higher survival rate compared to most other brain tumors, but early diagnosis and treatment are key. Oligodendroglioma belongs to a group of brain tumors called gliomas. Gliomas are primary tumors. This means they originated in the brain rather than spreading from elsewhere in the body. The National Brain Tumor Society reports that around 1.2% of all brain tumors are classified as an oligodendroglioma. They are typically divided into two types: grade 2 (slow growing) grade 3 (fast growing) Oligodendroglioma is more commonly diagnosed in adults, though young children can also be affected. Life expectancy and survival rate According to the American Cancer Society, the 5-year relative survival rate for people with an oligodendroglioma is as follows: 90% for those ages 22 to 44 years 82% for those ages 45 to 54 years 69% for those ages 55 to 64 years The relative survival rate suggests how long someone with a condition may live after receiving their diagnosis compared to someone without the condition of the same race, sex, and age over a specific time. This is different from overall survival rate, which is a percentage of people still alive for a specific time after receiving a diagnosis. It's most important to remember that these figures are estimates, and everyone is different. You can talk with your doctor about your specific condition. Several factors can affect your survival rate, including the grade of the tumor and how early it was diagnosed, as well as your overall health. Symptoms Oligodendroglioma can lead to a wide variety of symptoms. Seizure is the most common symptom — about 60% of people experience a seizure before receiving an oligodendroglioma diagnosis, according to the National Cancer Institute. Other symptoms include: headache cognitive changes weakness or numbness in the limbs issues with balance or movement However, the symptoms you experience can vary based on the size of the tumor and which part of your brain the tumor is growing in. What are the causes? There are no known causes of oligodendroglioma. Genetic changes are thought to play a role in the development of oligodendroglioma. Factors such as radiation exposure may also increase the risk of developing this type of tumor. Treatment options There are a number of treatment options available. You and your doctors will work together to decide what's the best course of action is in your case. Your medical team will base their decisions upon a number of factors, including: your overall health the grade and location of your tumor the final diagnosis given by a neurosurgeon Surgery Surgery is typically the first-line treatment for oligodendroglioma. The goal is to remove as much of the tumor as possible. Other treatment If the tumor cannot be completely removed with surgery, additional treatment may be used to avoid recurrence, such as: Radiation therapy: This involves the use of high energy rays. It's typically used after surgery to help kill any tiny fragments of the tumor that may remain. Chemotherapy: This treatment uses cytotoxic drugs to help kill cancer cells and can be used before and after radiotherapy. It's also useful for shrinking brain tumors, particularly those that cannot be surgically removed. Targeted therapy: This treatment can be used to slow tumor regrowth. Clinical trials: Your doctor may recommend enrolling in a clinical trial to test potential new treatment options. Antiseizure medication: If you experience seizures, these medications will likely be a part of your treatment plan. Outlook and recurrence The outlook for oligodendroglioma tumors depends on factors such as the tumor grade, the overall health of the person with the diagnosis, and how early the tumor was diagnosed. People who receive a diagnosis and begin treatment early have a higher chance of survival. Overall, those who have an oligodendroglioma tend to have a higher survival rate than most other brain tumors. Many treatment options are available, and oligodendroglioma appears to respond well to treatment. It's unusual to be able to completely remove the tumor, but it's possible to prolong the life of someone with an oligodendroglioma. Successful treatment plans often employ several methods. This reduces the chance that the tumor will recur. Like all other gliomas, oligodendroglioma has a very high rate of recurrence and often gradually increases in grade over time. Recurrent tumors are often treated with more aggressive forms of chemotherapy and radiation therapy.
Los Angeles Times
18-06-2025
- Health
- Los Angeles Times
USC Explores Electric Fields Approach to Attack Deadliest Form of Brain Cancer
A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a brain tumor diagnosis with few available effective treatments. According to the National Brain Tumor Society, the average survival for patients diagnosed with glioblastoma is eight months. The study finds that using Tumor Treating Fields therapy (TTFields), which delivers targeted waves of electric fields directly into tumors to stop their growth and signal the body's immune system to attack cancerous tumor cells, may extend survival among patients with glioblastoma when combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide). TTFields disrupt tumor growth using low-intensity, alternating electric fields that push and pull key structures inside tumor cells in continually shifting directions, making it difficult for the cells to multiply. Preventing tumor growth gives patients a better chance of successfully fighting the cancer. When used to treat glioblastoma, TTFields are delivered through a set of mesh electrodes that are strategically positioned on the scalp, generating fields at a precise frequency and intensity focused on the tumor. Patients wear the electrodes for approximately 18 hours a day. Researchers observed that TTFields attract more tumor-fighting T cells, which are white blood cells that identify and attack cancer cells, into and around the glioblastoma. When followed by immunotherapy, these T cells stay active longer and are replaced by even stronger, more effective tumor-fighting T cells. 'By using TTFields with immunotherapy, we prime the body to mount an attack on the cancer, which enables the immunotherapy to have a meaningful effect in ways that it could not before,' said David Tran, MD, PhD, chief of neuro-oncology with Keck Medicine, co-director of the USC Brain Tumor Center and corresponding author of the study. 'Our findings suggest that TTFields may be the key to unlocking the value of immunotherapy in treating glioblastoma.' TTFields are often combined with chemotherapy in cancer treatment. However, even with aggressive treatment, the prognosis for glioblastoma remains poor. Immunotherapy, while successful in many other cancer types, has also not proved effective for glioblastoma when used on its own. However, in this study, adding immunotherapy to TTFields and chemotherapy was associated with a 70% increase in overall survival. Notably, patients with larger, unresected (not surgically removed) tumors showed an even stronger immune response to TTFields and lived even longer. This suggests that when it comes to kick-starting the body's immune response against the cancer, having a larger tumor may provide more targets for the therapy to work against. This study demonstrates that combining TTFields with immunotherapy triggers a potent immune response within the tumor – one that ICIs can then amplify to bolster the body's own defense against cancer. 'Think of it like a team sport – immunotherapy sends players in to attack the tumor (the offense), while TTFields weaken the tumor's ability to fight back (the defense). And just like in team sports, the best defense is a good offense,' said Tran, who is also a member of the USC Norris Comprehensive Cancer Center. Keck Medicine is participating in the multicenter Phase 3 clinical trial to validate the efficacy of TTFields with immunotherapy and chemotherapy. Tran, who has been researching TTFields for more than a decade, serves as the chair of the steering committee for this trial. Frances Chow, MD, neuro-oncologist with USC Norris, is the principal investigator of the Keck Medicine study site. This Phase 3 trial, currently open at 28 sites across the United States, Europe and Israel, aims to enroll over 740 patients through April 2029, including those with gross total resection, partial resection or biopsy-only tumors to assess the extent of how surgically removing tumors influences immune response. Information was sourced from Keck Medicine. To learn more, contact
India Today
08-06-2025
- Health
- India Today
Don't miss the signs: Doctors warn of brain tumor surge among children
A growing number of children and young adults are being diagnosed with brain tumors, a condition once thought to largely affect the recent years, doctors across India are witnessing a disturbing trend: more cases of brain tumors being detected among children and individuals in their 20s and 30s, many of which are being diagnosed too late for optimal most cases cannot be pinpointed, doctors say increasing awareness, timely medical intervention, and parental vigilance can reduce this alarming trend. "Although brain tumors are more common in adults, even younger kids can be affected by this condition. According to the National Brain Tumor Society, approximately 5.7% of all primary brain tumors occur in children and adolescents aged 0-19 years. These tumors may be benign or malignant, but either way, timely medical care is vital," says Dr. Anurag Saxena, neurosurgeon at Manipal symptoms of brain tumors in children can often mimic more common conditions, leading to delays in Saxena explains that in infants, abnormal skull growth may be an early sign, while older children may show symptoms like seizures, excessive crying, unresponsiveness, or vision teenagers, persistent headaches, dizziness, vomiting, or coordination problems can indicate the presence of a diagnosis is especially critical in children, as their developing brains are more vulnerable to damage. Diagnostic imaging such as MRI or CT scans remains the cornerstone of identifying these tumors.'Sometimes, benign tumors can be removed completely through surgery. But to avoid long-term damage, it's essential to catch these conditions early,' added Dr. pattern is not restricted to children alone. An increasing number of young adults, especially those aged 20 to 40, are also being diagnosed with brain tumors, a shift that medical experts are calling "alarming.""Brain tumors have historically been viewed as a problem primarily affecting older adults,' says Dr. Varindera Paul Singh, neurosurgeon at Medanta. 'However, data and clinical evidence now indicate an alarming increase in brain tumors among individuals aged 20 to 40. This shift calls for a renewed approach to brain health awareness within the younger population.'Dr. Singh points out that while improved imaging technologies like MRI have led to better detection rates, they alone cannot explain the rising factors, lifestyle-related stress, and genetic predispositions are also believed to contribute, although more research is needed to confirm this.A key challenge, he says, is that symptoms in younger adults, such as fatigue, nausea, or mild behavioural changes, are often brushed off as stress or these changes are often subtle, many young patients ignore their symptoms altogether, allowing tumors to grow unnoticed. It is crucial to educate both the public and primary care providers that brain tumors can occur at any age," says Dr. children, too, the signs can be subtle, but should never be overlooked. Dr. Shiji Chalipat, pediatric neurologist at Ankura Hospital for Women and Children, highlights that immediate medical attention can be lifesaving.'Parents need to be proactive when it comes to their child's health. Just like adults, brain tumors are a common occurrence in children. Unfortunately, these tumors are linked to high morbidity and mortality, making early diagnosis and treatment crucial for improving quality of life," she Chalipat has outlined several red flags for parents to look out for:advertisementVomiting and Headaches: Persistent vomiting, especially in the morning or when coupled with headaches, could signal increased pressure inside the Impairments: Difficulty with vision, hearing, or speech may indicate tumor growth depending on its and Coordination Issues: Tumors affecting the brainstem may result in imbalance or trouble Changes: Sudden mood swings, irritability, or withdrawal should not be dismissed as mere Especially if they are new or unexplained, seizures are a strong warning sign and require urgent plans often include surgery, chemotherapy, or radiation depending on the tumor's size, location, and type.'Parents play a critical role in recognising and responding to these warning signs,' advises Dr. Chalipat. 'With prompt action, we can ensure children receive the right medical and surgical care, and the best possible chance at recovery.'The growing prevalence of brain tumors in both children and young adults is a sobering reminder of the need to stay vigilant. Whether it's a toddler showing signs of imbalance or a young professional battling persistent headaches, the message from doctors is clear: don't ignore the diagnosis can be the difference between life and death or between lasting damage and full Reel
Yahoo
10-05-2025
- Health
- Yahoo
Hundreds gather to raise money, awareness for brain cancer research
Hundreds of people braved the chilly rain on Saturday morning to take part in the Georgia Brain Tumor Walk and Race to raise money and awareness for brain cancer research. Channel 2's Bryan Mims and several other members of the WSB-TV family were at the race for a cause near and dear to Channel 2 Action News. The third annual event hosted by the National Brain Tumor Society saw about 1,200 people sign up to walk or run the 5K race near Truist Park. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] For the WSB-TV family, it gives us and the community a chance to remember Channel 2's Jovita Moore, who died in Oct. 2021 after a battle with glioblastoma, the most common type of brain cancer. At this time, there is no cure for glioblastoma, only treatments to slow it down. 'It really showed me how strong she really is. Once I seen that, I was like, 'I can do the same thing too.' That inspired me to do anything I want,' her son Josh Griffith said. Angela Wright, a teacher from Senoia, was diagnosed with glioblastoma last August, but isn't giving up the fight. TRENDING STORIES: 4.1 magnitude earthquake reported in Tennessee, felt all the way in metro Atlanta Neighbors told to shelter in place after Henry County tire shop catches fire Buc-ee's announces opening date for new Georgia location 'This is what gets me through,' she said. 'I had chemo this week and I had kind of a down week, but knowing this was coming up at the end of the week and to get to see my people, it lifts my spirits.' The goal of the race was to raise $200,000 to fund research into new medicines, treatments and, hopefully, a cure. Even though the race is over, you can still donate by clicking here. [SIGN UP: WSB-TV Daily Headlines Newsletter]
